目的：研究脾栓塞治疗肝癌患者脾功能亢进的疗效。方法选择我院2014年1月～2015年10月收治的肝癌脾功能亢进患者128例作为研究对象。随机将其分为常规组和脾栓塞组，各64例。常规组仅给予肝动脉化疗栓塞，脾栓塞组在常规组基础上结合脾栓塞治疗。比较两组患者一次性插管成功率、并发症发生率；手术前和手术后1周患者肝功能相关指标的差异。结果脾栓塞组相较于常规组一次性插管成功率、并发症发生率无显著差异，均插管成功，无严重并发症发生，差异无统计学意义（P＞0.05）；手术前两组肝功能相关指标相似，差异无统计学意义（P＞0.05）；手术后1周脾栓塞组肝功能相关指标无显著变化，常规组则出现肝功能明显受损现象，差异有统计学意义（P＜0.05）。结论脾栓塞治疗肝癌患者脾功能亢进的疗效确切，手术安全，成功率高，且可减轻肝功能损害，缓解临床症状，值得推广。

目的:探讨血管介入治疗原发性肝细胞型肝癌的临床研究.方法:本次研究对象来源于我院介入科2010.2～2012.2收治的原发性肝细胞型肝癌患者120例,依据治疗方式分组,其中A组(n=60)采用TAE(经导管肝动脉栓塞)治疗,B组(n=60)采用TACE(肝动脉灌注化疗栓塞),比较两组临床效果.结果:A组患者治疗总有效率为73.33％,B组患者总有效率为75.0％,组间差异不明显(P＞0.05).A组和B组患者的毒副反应发生情况比较,不具有统计学意义(P＞0.05).两组总体1～3年生存率对比P＞0.05,但在肿瘤直径超过10cm患者中B组1年生存率为45.0％,2年为33.3％,3年为25.0％,明显高于A组,对比P＜0.05.结论:对原发性肝细胞型肝癌患者行TAE与TACE均有优良效果,但在肿瘤直径超过10cm患者中TACE有更优良的远期疗效,值得临床推广使用.

目的 研究TACE联合射频消融术治疗原发性肝癌的疗效.方法 选取我院2013年1月~2014年1月原发性肝癌患者60例,将其随机分为A组和B组,各30例.A组行TACE治疗,B组行TACE联合射频消融术治疗.对两组患者血清甲胎蛋白降低率和治疗总有效率、2年生存率、术后并发症率进行比较.结果 B组治疗总有效率、2年生存率明显高于A组,差异有统计学意义(P<0.05);两组患者术后并发症发生率比较,差异无统计学意义(P>0.05);B组血清甲胎蛋白降低率明显优于A组,差异有统计学意义(P<0.05).结论 TACE联合射频消融术治疗原发性肝癌的疗效确切,可缓解患者临床症状,延长生存期,手术安全有效,值得临床推广.

Objective:To exp10re the three periods of enhanced CT in the diagnosis of primary liver cancer after interventional re- sidual carcinoma clinical significance.Methods:The study object from our involvement in secco admitted 180 patients with primary liver cancer after interventional residual carcinoma,all three periods of enhanced CT scan,to study the efficacy of interventional operation. Results:Type giant piece of tumor in patients with rare (14.2%),tubercle patients without rare,contrast P<0.05.Conclusion:The third phase of enhanced CT in the diagnosis of primary liver cancer after interventional residual carcinoma clinical value is high,is worth promoting.

Objective To analyze the effect of application of bronchial artery embolization in the treatment of massive hemoptysis.Methods The clinical data of 47 patients with massive hemoptysis treated were retrospectively analyzed from January 2012 to April 2015.Results47 patients, 29 cases of unilateral lesions, 18 cases of bilateral lesions; 46 patients were treated immediately after hemostasis, early recurrence in 4 patients, 3 cases of recurrence of medium-term, 2 cases of recurrence of forward; 2 cases are transient fever, 1 case of puncture region bleeding, 1 case of chest pain.ConclusionThe clinical effect of bronchial artery embolization in the treatment of massive hemoptysis was signiifcant, and the rate of hemostasis was high. The possibility of complications was very small.

Objective To evaluate the effect of treating lung cancer through bronchial artery medication(drug treatment).Method Total 16 patients with lung cancer treated by bronchial artery infusion(BAI),and the changes of the tumor diameter,alleviation of clinical symptoms and complications following infusion were observed.Results The diameter of tumor shrunk to be smaller after BAI,most of the clinical symptoms were also alleviated and no major complication occured.Conclusion The effect and the safety are good after treating lung cancer with BAI.

Objective:To study clinical therapeutic effctiveness of combined 3-dimensional conformal radiotherapy (3-DCRT) and transcatheter arterial chemoembolization for portal vein tumor thrombus (PVTT) in unresectable hepatocellular carcinoma(HCC). Methods:228 HCC patients with tumor thrombus in the portal vein were divided into two groups randomly.Group A(102 cases)was treated with TACE only; while group B (126 cases) with 3-DCRT combined with TACE. The gross tumor volume (GTV)was defined as only PVTT. RT was started 1.2 fractions following TACE.A total dose of 45-60 Gy was given as daily 2-4 Gy fractions,with the gross tumor volume (CTV)defined as only PVTT,85%～90% isodose line covering 100% PTV. Results:Survival rates of group A at 1,1.5 and 2 years were 12.7%,9.4% and 3.9% respectively with the mean survival time (MST) of 7.2 months,while those of group B were 54.0%,40.1% and 27.4%,median survival time were 7.2 months and 18.6 months. The total effective rates of group A and B were 39.2%(40 / 102) and 83.3%(105 / 126) respectively. There was significant difference between the two groups (P0.05). Conclusion:3-DCRT combined with TACE can elevate the therapeutic effect of portal vein tumor thrombus in hepatocellular carcinoma.